Mobile

A Phase III, multicentre, double–blind, placebo controlled, cross over study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of afamelanotide in the treatment of solar urtic...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002143-16

A Phase III, multicentre, double–blind, placebo controlled, cross over study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of afamelanotide in the treatment of solar urticaria (SU)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective: To determine if afamelanotide increases the minimal urticarial dose (MUD) in subjects with solar urticaria (SU).

Critère d'inclusion

  • Solar Urticaria (SU)

Liens